Skip to main content
GLP-1 Agonists

Can Ozempic Make You Blind? Here’s How GLP-1 Medications Could Affect Your Vision

Sophie Vergnaud, MDAlyssa Billingsley, PharmD
Written by Sophie Vergnaud, MD | Reviewed by Alyssa Billingsley, PharmD, Nishika Reddy, MD
Updated on June 27, 2025

Key takeaways:

  • New research has shown a link between taking semaglutide (Ozempic, Wegovy) and an increased risk of a serious eye condition called macular degeneration.

  • Research has also linked semaglutide to a rare kind of eye stroke called non-arteritic anterior ischemic optic neuropathy (NAION). But the risk is lower than previously thought. 

  • Semaglutide has further been linked to short-term changes in vision, especially in people with diabetic eye disease. 

  • For most people, the benefits of taking semaglutide likely still outweigh the possible risks. But the risks may be higher for people with underlying eye disease or those who take semaglutide long term. 

Semaglutide — the active ingredient in Ozempic and Wegovy — has transformed treatment for Type 2 diabetes and weight loss. More and more people are using these medications, which belong to a class known as glucagon-like peptide-1 (GLP-1) receptor agonists. With the surge in use, researchers and medical experts are paying closer attention to their potential side effects, including some that affect the eyes.

In recent months, a growing number of studies have raised questions about whether semaglutide may increase the risk of certain vision problems. These problems include serious conditions like diabetic retinopathy, age-related macular degeneration (AMD), and a rare type of eye stroke called non-arteritic anterior ischemic optic neuropathy. 

So, can semaglutide actually harm your vision — or are the headlines overblown? Here’s what the latest evidence shows and what symptoms to watch for, along with how to protect your eye health if you’re taking a GLP-1 medication.

Why might semaglutide affect vision?

Experts aren’t exactly sure how medications like semaglutide could lead to eye problems like AMD, worsening diabetic retinopathy, and eye strokes. But there are a few theories. 

One idea is that semaglutide lowers blood sugar levels very quickly, especially in people with diabetes. These fast changes in blood sugar might affect oxygen supply to blood vessels in the eyes.

Another theory is that the GLP-1 receptors these medications act on are found throughout the body, including in the retina (the part of the eye that helps you see clearly).

So let’s look at what the research to date tells us on what the risks of semaglutide are for your vision. 

Semaglutide and diabetic eye disease

The most important question for people with Type 2 diabetes taking semaglutide is whether semaglutide helps or worsens diabetic eye disease (diabetic retinopathy). Diabetic retinopathy happens when high blood glucose levels damage the blood vessels in the light-sensitive tissue at the back of the eye (the retina). It’s a major cause of vision loss in people with diabetes. 

A 3D illustration of diabetic retinopathy highlighting the retina, optic nerve, lens, and macula.

One important study (the SUSTAIN-6 trial) suggests semaglutide can worsen diabetic retinopathy temporarily in people who already have a severe form of it. This may seem surprising: How can a medication that improves blood glucose levels worsen diabetic retinopathy? 

GoodRx icon

The link between semaglutide and worsening diabetic retinopathy may be due to the rapid improvement in blood glucose levels that comes with starting the medication. Keeping blood glucose levels “in range” is important for long-term health in people with diabetes. But in the short term, these rapid improvements can sometimes make diabetic retinopathy worse before it gets better. This phenomenon has been observed with other diabetes treatments too.

However, not all studies agree. Other research from the American Academy of Ophthalmology found that nearly 60% of people with advanced diabetic eye disease actually experienced improvement in their diabetic eye disease while taking the medication. 

To help answer this question more definitively, a large ongoing 5-year study called FOCUS is tracking about 1,500 people over several years to better understand the impact of medications like semaglutide on diabetic eye disease. The results are expected in 2027.

Semaglutide and macular degeneration

Some new research suggests that semaglutide might slightly raise the risk of a serious eye disease called neovascular age-related macular degeneration, or wet AMD for short. This is the less common but more serious type of AMD.

Wet AMD happens when tiny blood vessels grow under the macula (the central part of the retina). These blood vessels can leak or bleed, which can lead to blurry vision or even permanent vision loss. This condition mostly affects older adults and gets worse over time if not treated.

A big study in Canada looked at people over age 65 who were using GLP-1 medications like semaglutide. Researchers found that people taking these medications were about twice as likely to be diagnosed with wet AMD compared to people not using them. The risk was still low overall: about 2 out of every 1,000 people. But it was higher than expected.

Semaglutide and blindness from NAION

Research in JAMA Ophthalmology in 2024 and 2025 found a link between people who took semaglutide and a rare kind of eye stroke called non-arteritic anterior ischemic optic neuropathy (NAION). Researchers had noticed a cluster of cases of NAION in summer 2023 in people taking semaglutide. And they wanted to understand if it was more than a coincidence. 

The large-scale study published in 2025 looked at over 37 million people across 14 global health databases. Here are the takeaways from the study:

  • People taking semaglutide had a higher risk of developing NAION compared to before starting the drug. The risk was estimated to be 1.3 times higher than people not taking semaglutide. 

  • But this increased risk was lower than previously thought. 

  • And, importantly, the condition itself is rare. Out of 100,000 people, up to 10 people are affected by it each year. 

  • So, even with an increased risk, the risk is still low. 

But NAION is very serious: It can cause permanent blindness in one eye. This vision loss is painless. It comes on suddenly and typically gets worse over a few days before stabilizing. And there are no treatments that can improve or reverse it. 

Diagnosing it is difficult, and understanding why it happens is still a mystery. Experts think it happens as a result of reduced blood flow to the optic nerve. 

So, can Ozempic cause blindness?

It’s too early to say. The research does signal a link between semaglutide and certain forms of eye disease including blindness. However, this link is just that: a link. It doesn’t mean that taking semaglutide caused the cases of blindness and macular degeneration. In fact, showing the link is only the first step. Proving that the medication causes these conditions is much more challenging.

And it’s possible that the vision problems linked to semaglutide may not be caused by the medication at all. Instead, they could be a result of the rapid cardiovascular and metabolic changes that happen when a person starts taking semaglutide. 

According to Nishika Reddy, MD, another possibility is that semaglutide is just the common thread linking these cases together. After all, you’re more likely to have vision problems if you have conditions like: 

  • High blood pressure

  • Obstructive sleep apnea

  • Diabetes

  • Excess weight

These conditions are more common in people who take semaglutide.

Should you take semaglutide?

It can feel scary to add another risk to your health — especially if you’re already living with the health risks of diabetes and other cardiovascular and metabolic conditions. 

The truth is, we don’t know everything about the short- and long-term impacts of medications like semaglutide. But there is clear information about the long-term health risks of living with diabetes, cardiovascular disease, and excess weight

So, like many things in life (and healthcare), it’s a question of balancing risks and benefits. And deciding if the benefits are worth the risks — or not — is entirely unique to you and your situation. 

Who’s at risk?

Some people may be less able than others to take on the risk to their vision. These may include: 

  • Older adults

  • People with pre-existing eye disease, like vision loss, macular degeneration, or glaucoma

When it comes to the risk of NAION, Dr. Reddy explained that certain conditions affect the structure of the eye and create crowding at the back of the eye, where the optic nerve connects. This location is called the optic disc. According to Dr. Reddy, conditions that put your “disc at risk” can increase your risk of NAION. 

Overall, Dr. Reddy said that "while the risk of developing these conditions is low, it’s important for people to be aware of the possible eye side effects related to these types of medications.” 

She advises thinking about how long you plan to take the medication. “When it comes to macular degeneration,” she said, “the risk was highest in people who’d taken these medications the longest, according to the study.”

How to lower your risk

In the meantime, if you take or are considering taking semaglutide for diabetes, and you’re worried about your eye health, speak with a healthcare professional you trust. That could be your primary care provider, your diabetes or weight specialist, or your eye care specialist. Let them know what medications you’re taking. And tell them about your medical history (if they don’t already know it). Be honest about your fears. 

There are precautions you can take to lower your risk of eye complications from semaglutide, such as: 

  • If you have diabetes and are starting semaglutide, get a detailed eye exam first — especially if you’ve had eye problems before. 

  • If you’re not sure how healthy your optic disc is, schedule a routine eye exam with your eye doctor. It’s a good idea to do this once a year anyway.

  • Let your eye doctor know if you notice any changes in your vision, like blurriness, dark spots, floaters, flashes, or trouble seeing at night. 

Most people can take semaglutide safely, but watching your eyes closely is an important part of staying healthy.

Frequently asked questions

It’s possible that starting semaglutide can cause blurred vision. This is related to blood glucose levels dropping rapidly. When your blood glucose levels change, this can affect the shape of the eye’s lens. This can cause blurry vision, and it often happens as a symptom of dangerously low blood glucose levels (hypoglycemia).

Older adults may be more likely to experience blurred vision when starting semaglutide. That’s because the eye’s lens becomes less flexible with age. For some people, it may take longer for vision to stabilize after starting semaglutide. But this side effect should go away within a few months of starting semaglutide (or changing the dose).

Some side effects of semaglutide — like nausea, vomiting, and fatigue — are usually temporary and go away after the body adjusts or the medication is stopped. But rare and more serious side effects, like vision problems or pancreatitis, can lead to lasting complications. It’s important to monitor symptoms closely and talk to your doctor about any changes. 

The bottom line

Semaglutide (Ozempic, Wegovy) helps many people lose weight and manage blood sugar, and it improves many related health conditions. But there may be a small increased risk of serious eye conditions like diabetic retinopathy, age-related macular degeneration (AMD), and a rare type of eye stroke that causes sudden vision loss. While the risks appear to be low overall, they may be higher for some people, especially those with underlying eye disease or long-term use. Staying informed, watching for symptoms, and getting regular eye checks are key. 

why trust our exports reliability shield

Why trust our experts?

Sophie Vergnaud, MD, is the Senior Medical Director for GoodRx Health. A pulmonologist and hospitalist, she practiced and taught clinical medicine at hospitals in London for a decade before entering a career in health education and technology.
Alyssa Billingsley, PharmD, is the director of pharmacy content for GoodRx. She has over a decade of experience as a pharmacist and has worked in clinical, academic, and administrative roles.
Nishika Reddy, MD
Reviewed by:
Nishika Reddy, MD
Nishika Reddy, MD, is an attending physician at the University of Utah. She provides comprehensive and cornea medical care at the Moran Eye Center and serves as clinical assistant professor.

References

GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.

Was this page helpful?

Latest articles